Curis (CRIS)
(Delayed Data from NSDQ)
$16.51 USD
+0.52 (3.25%)
Updated May 2, 2024 04:00 PM ET
After-Market: $16.72 +0.21 (1.27%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Brokerage Reports
Curis, Inc. [CRIS]
Reports for Purchase
Showing records 81 - 100 ( 302 total )
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
''427 Back On Track; We''re Happy; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Meeting With Management; Focused Clinical Dev is the Word; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Dropping Coverage Due to Analyst Departure
Provider: WEDBUSH SECURITIES INC.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Q1:14 Update - CRIS Remains Undervalued - Q1 Erivedge Sales Historically Light, Expecting Uptick in Q2
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
1Q14 Results; Erivedge Growing and Pipeline Progressing; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Data in the CUDC-907, CUDC-427 and Debio 0932 Programs Highlight Anti-Tumor Activity and Potential Biomarkers
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
427 Gets Green Light to Move Ahead; Overhang Removed; Target to $10
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
CUDC-427 Clinical Hold Lifted - Phase Ib/II in Breast Cancer to Start Mid-2014 - ''427 Immunomodulatory Effects Overlooked - Biomarker Data at AACR
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.